Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorNorthwestern University
About this trial
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises
ages 18 to 50
con provide informed consent in English
Disqualifiers
Age under 18 or above 50
gestational ages before 16 weeks 0 days or after 20 weeks 0 days
unable to provide written consent in English
hypertensive disorder
Trial design
Design model
Parallel
Treatments tested in this trial
Cabergoline
Drug1mg oral cabergoline given to participants once
Placebo
Drug1 encapsulated placebo tablet given to participants after procedure
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: CabergolineExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
breast symptoms
Using the bristol breast inventory to assess breast symptoms (engorgement, lactation, etc).
Time frame
3 days post procedure and two weeks post procedureSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov